Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 15;7(2):153-171.
doi: 10.31662/jmaj.2023-0171. Epub 2024 Apr 1.

Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis

Anindita Das Barshan  1   2 , Emilie Louise Akiko Matsumoto-Takahashi  1
Affiliations
Review

Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis

Anindita Das Barshan et al. JMA J. .

Abstract

Background: The possibility of developing a severe coronavirus infectious (COVID-19) disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has increased, particularly in patients with hematological malignancies. These patients are more likely to produce less antibody protection due to the immunocompromised nature of the disease and the anticancer treatments. Therefore, the present systematic review intended to evaluate the seroconversion rate of COVID-19 vaccines in patients with hematological malignancies compared with healthy controls.

Methods: A comprehensive systematic search was conducted in Medline via PubMed, EMBASE, and the World Health Organization COVID-19 Research Database, as well as other searches (i.e., reference list from article search and manual searches), from December 2020 to May 2022. The outcome of interest included estimating the seroconversion rates following COVID-19 vaccination in patients with hematological malignancies and comparing them with those in healthy controls. After two-step screening, the data were extracted and the summary measures were calculated using a random-effects model.

Results: A total of 39 articles regarding patients with hematological malignancies were included in the present review. After the first vaccine dose, these patients had considerably lower antibody response rates (37.0%) compared with healthy controls (74.5%). Following the second vaccine dose, the seroconversion rate in patients reached 66.8%, whereas it peaked at 97.9% in the healthy controls following complete immunization. Notably, the BNT162b2 and ChAdOx1 vaccine combination achieved the highest seropositivity rate of approximately 70%. Multiple myeloma, chronic lymphocytic leukemia, and lymphoma were the cancers of interest in most of the studies.

Conclusions: The results of the present study highlighted the comparatively low seropositivity rates in patients with hematological malignancies, with substantial variations in rates across disease groups. The findings emphasize the possibility of additional booster doses for these individuals to enhance their immunity against SARS-CoV-2.

Keywords: COVID-19 vaccines; Hematological malignancy; Immunogenicity; Seroconversion; Systematic review.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1.
Figure 1.
Flowchart of the article selection process.
Figure 2.
Figure 2.
Risk ratios for seroconversion among patients with hematological malignancies compared with healthy controls after the first dose of the COVID-19 vaccine.
Figure 3.
Figure 3.
Risk ratios for seroconversion among patients with hematological malignancies compared with healthy controls after the second dose of the COVID-19 vaccine.
Figure 4.
Figure 4.
Funnel plot of the results for the first and second vaccine doses.
See this image and copyright information in PMC

References

    1. Mullard A. Pfizer’s COVID-19 vaccine secures first full FDA approval. Nat Rev Drug Discov. 2021;20(10):728. - PubMed
    1. Addeo A, Shah PK, Bordry N, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39(8):1091-98.e2. - PMC - PubMed
    1. Rugge M, Zorzi M, Guzzinati S. SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer. Nat Cancer. 2020;1(8):784-8. - PubMed
    1. Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43-50. - PMC - PubMed
    1. Keykhaei M, Masinaei M, Mohammadi E, et al. A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990-2017. Exp Hematol Oncol. 2021;10(1):1-5. - PMC - PubMed

LinkOut - more resources